Published in

American Association for Cancer Research, Cancer Epidemiology, Biomarkers & Prevention, 6(22), p. 1102-1109, 2013

DOI: 10.1158/1055-9965.epi-12-1046

Links

Tools

Export citation

Search in Google Scholar

Diabetes Mellitus and Prostate Cancer Risk; A Nationwide Case-Control Study within PCBaSe Sweden

Journal article published in 2013 by Katja Fall, Hans Garmo, Soffia Gudbjornsdottir, Pär Stattin, Björn Zethelius
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Abstract Background: Diabetes mellitus (DM) increases the risk for cancer at almost all sites, but data on the association with prostate cancer are inconsistent. Methods: We assessed the risk of a prostate cancer diagnosis among men with type 2 (T2)DM in a nationwide population-based case-control study including 44,352 men with prostate cancer identified through the Prostate Cancer data Base Sweden (PCBaSe) between 2002 and 2006 and 221,495 age-matched men from the general population. Results: Overall, the risk of prostate cancer among men with T2DM was lower than among men without T2DM [OR, 0.80; 95% confidence interval (CI), 0.76–0.85]. The risk decreased with longer disease duration and was observed across all tumor risk categories, although most clearly among men with low risk tumors (OR, 0.71; 95% CI, 0.64–0.80). The risk for prostate cancer was reduced among diabetic men on dietary treatment only (OR, 0.89; 95% CI, 0.80–0.99) but more markedly among men on oral hypoglycemic agents (OR, 0.80; 95% CI, 0.74–0.87) and insulin (OR, 0.72; 95% CI, 0.69–0.81). Obese diabetic men (BMI > 30 kg/m2) showed a reduced risk (OR, 0.72; 95% CI, 0.65–0.80) compared with men without diabetes. There was a trend of decreasing risk with increasing levels of HbA1c (P < 0.05). Conclusions: This nationwide study confirmed a reduced risk of being diagnosed with prostate cancer among men with T2DM, especially for low-risk tumors. An altered hormonal milieu is a plausible explanation, although the possibility of decreased prostate cancer detection among diabetic men cannot be ruled out. Impact: This is the largest study to examine the association between T2DM and prostate cancer accounting for tumor risk group and diabetes treatment. Cancer Epidemiol Biomarkers Prev; 22(6); 1102–9. ©2013 AACR.